Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 73.41B 65.23B 60.88B 55.49B 105B 7,057B 106B 737B 285B 3,608B 276B 270B 11,579B P/E 2026 *
16.8x
P/E 2027 * 14.5x
Enterprise Value 65.99B 58.63B 54.72B 49.88B 94.07B 6,344B 94.95B 662B 257B 3,243B 248B 242B 10,408B EV / Sales 2026 *
3.88x
EV / Sales 2027 * 3.41x
Free-Float
71.06%
Yield 2026 *
0.53%
Yield 2027 * 0.6%

Last Transcript: Regeneron Pharmaceuticals, Inc.

1 day+0.05%
1 week-6.71%
Current month-3.04%
1 month-11.18%
3 months+12.37%
6 months-3.50%
Current year-4.75%
1 week 726.02
Extreme 726.02
777.43
1 month 726.02
Extreme 726.02
821.17
Current year 591.52
Extreme 591.52
859.34
1 year 541
Extreme 541
859.34
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Sell

Executive/Senior Manager

-1,131 0.0011%
02/09/26 Exercice

Director

1,200 0.0012%
19/08/26 Exercice

General Counsel

33,583 0.0326%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-6.71%+22.53%-9.79% 73.41B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+0.94%-1.83%+20.98%+41.43% 333B
+1.07%-3.16%+11.12%+34.77% 267B
+0.19%-4.82%-6.57%+9.07% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.16%-3.86%+25.77%+51.98% 377.06B
Weighted average by Cap. -0.19%-3.60%+29.00%+69.12%

Financials

2026 *2027 *
Net sales 17.01B 15.12B 14.11B 12.86B 24.25B 1,636B 24.48B 171B 66.16B 836B 63.88B 62.49B 2,683B 18.51B 16.45B 15.35B 13.99B 26.39B 1,780B 26.63B 186B 71.99B 910B 69.5B 67.99B 2,920B
Net income 4.95B 4.4B 4.11B 3.74B 7.06B 476B 7.12B 49.69B 19.26B 243B 18.59B 18.19B 781B 5.49B 4.87B 4.55B 4.15B 7.82B 527B 7.89B 55.05B 21.33B 270B 20.6B 20.15B 865B
Net Debt -7.42B -6.59B -6.15B -5.61B -10.58B -714B -10.68B -74.48B -28.86B -365B -27.87B -27.26B -1,171B -10.32B -9.17B -8.55B -7.8B -14.71B -992B -14.84B -104B -40.12B -507B -38.73B -37.89B -1,627B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
02/10/26 $735.20 +0.05% 613,949
01/10/26 $734.81 -3.09% 1,042,865
30/09/26 $758.27 +1.03% 872,457
29/09/26 $750.51 -0.23% 804,336
28/09/26 $752.25 -4.54% 1,149,832
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
735.20USD
Average target price
853.19USD
Spread / Average Target
+16.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock